| P2093 | author name string | Tron F | |
| | Le Loët X | |
| | Jouen-Beades F | |
| | Vittecoq O | |
| P2860 | cites work | Nomenclature of systemic vasculitides. Proposal of an international consensus conference | Q29616304 |
| | Characteristics and pathogenic role of anti-beta2-glycoprotein I single-chain Fv domains: induction of experimental antiphospholipid syndrome | Q33330858 |
| | Localization of the apoptosis-inducing activity of lupus anticoagulant in an annexin V-binding antibody subset | Q33502380 |
| | Lessons from experimental APS models. | Q33504237 |
| | Complement-activating rheumatoid-factor-containing complexes in patients with rheumatoid vasculitis | Q33554141 |
| | Vasculitis in patients with systemic sclerosis and severe digital ischaemia requiring amputation | Q33566329 |
| | Anticardiolipin, anticentromere and anti-Scl-70 antibodies in patients with systemic sclerosis and severe digital ischaemia | Q33566574 |
| | Factors associated with the development of vasculitis in rheumatoid arthritis: results of a case-control study | Q33578798 |
| | International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA) | Q33587279 |
| | What is new with anti-neutrophil cytoplasmic antibodies: diagnostic, pathogenetic and therapeutic implications | Q33716991 |
| | Biologic and clinical significance of cryoglobulins. A report of 86 cases | Q34204386 |
| | Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl | Q36365371 |
| | IgG3 reactive rheumatoid factor in rheumatoid arthritis: etiologic and pathogenic considerations | Q40402305 |
| | Leg ulceration in rheumatoid arthritis | Q40644505 |
| | Sequence homologies between hsp60 and autoantigens | Q40893816 |
| | Pathology and pathogenesis of vascular injury in systemic lupus erythematosus. Interactions of inflammatory cells and activated endothelium | Q40937887 |
| | Anti-endothelial cell antibodies: only for scientists or for clinicians too? | Q40984244 |
| | Immune complexes in sera from patients with rheumatoid vasculitis induce polymorphonuclear cell-mediated injury to endothelial cells | Q41438839 |
| | Antibodies to DNA. | Q41756806 |
| | A role for hepatitis C virus infection in type II cryoglobulinemia | Q42983385 |
| | Mixed cryoglobulinemia and hepatitis C virus | Q43035467 |
| | Hepatitis C virus and cryoglobulinemia | Q45050069 |
| | Antilactoferrin antibodies in patients with rheumatoid arthritis are associated with vasculitis | Q45233268 |
| | Hepatitis C virus in patients with cryoglobulinemia type II. | Q45852251 |
| | Complement-mediated inhibition of immune precipitation in rheumatoid vasculitis | Q46105338 |
| | Are autoantibodies active players or epiphenomena? | Q48023157 |
| | Nomenclature and classification of vasculitis: plus ça change, plus c'est la même chose | Q48797565 |
| | The incidence of rheumatoid vasculitis in the Norwich Health Authority. | Q50602562 |
| | Peripheral neuropathy with necrotizing vasculitis in rheumatoid arthritis | Q59400174 |
| | Association of anti-beta 2 glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus | Q68008000 |
| | Selective pathogenicity of murine rheumatoid factors of the cryoprecipitable IgG3 subclass | Q68064189 |
| | IgG and IgA antibodies to the collagen-like region of C1q in rheumatoid vasculitis | Q68432583 |
| | Anticardiolipin antibodies in patients with rheumatic diseases | Q69198661 |
| | Antineutrophil cytoplasmic antibodies in rheumatoid arthritis patients | Q71066052 |
| | Induction of heat shock protein in monocytic cells by oxidized low density lipoprotein | Q71184020 |
| | A need for standardization of the anti-endothelial-cell antibody test | Q71711323 |
| | Immunization with anti-neutrophil cytoplasmic antibody (ANCA) induces the production of mouse ANCA and perivascular lymphocyte infiltration | Q71730880 |
| | Antibody to annexin V has anti‐phospholipid and lupus anticoagulant properties | Q71969567 |
| | Classification and epidemiology of systemic vasculitis | Q71987709 |
| | Anti-endothelial cell antibodies in sera of patients with autoimmune diseases: comparison between ELISA and FACS analysis | Q71997934 |
| | Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus | Q72214273 |
| | Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL | Q72235735 |
| | Disease distribution of beta 2-glycoprotein I-dependent anticardiolipin antibodies in rheumatic diseases | Q72253648 |
| | Antineutrophil cytoplasmic antibodies in rheumatoid arthritis. Characterization and clinical correlations | Q72861334 |
| | Involvement of beta 2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages | Q73149303 |
| | [New targets of antiphospholipid antibodies] | Q73361307 |
| | Prospective evaluation of the frequency and clinical significance of antineutrophil cytoplasmic and anticardiolipin antibodies in community cases of patients with rheumatoid arthritis | Q73893786 |
| | Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction | Q73965948 |
| | Antiphospholipid antibodies, annexin V, and pregnancy loss | Q73972710 |
| | Antineutrophil cytoplasmic antibodies | Q77341355 |
| | Early anti-nucleosome autoantibodies from a single MRL+/+ mouse: fine specificity, V gene structure and pathogenicity | Q77646934 |
| | Atherosclerosis-related markers in systemic lupus erythematosus patients: the role of humoral immunity in enhanced atherogenesis | Q77794855 |
| | Extra-articular rheumatoid arthritis: prevalence and mortality | Q78169221 |
| P433 | issue | 6 | |
| P304 | page(s) | 466-476 | |
| P577 | publication date | 2001-12-01 | |
| P1433 | published in | Joint Bone Spine | Q15752403 |
| P1476 | title | Antibodies and vascular involvement in inflammatory joint disease: clinical relevance | |
| P478 | volume | 68 | |